EUVIMEDEUVIMED entdecken
Crossref

Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low‐Dose Estramustine in Very High‐Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy

Takanari Kambe iD, Masashi Kubota, Toshinari Yamasaki iD, Mutsushi Kawakita, Shiori Murata, Yuto Hattori, Yoichiro Tohi, Yuya Sekine, Ryoma Kurahashi, Kimihiro Shimatani, Atsuro Sawada, Hiromitsu Negoro und 3 weitere

The Prostate · 2025

DOI: 10.1002/pros.24875 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, 2025. Verfasst von Takanari Kambe und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Estramustine, Prostatectomy, Gonadotropin-Releasing Hormone. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

High‐risk patients with prostate cancer (PC) frequently experience biochemical recurrence (BCR) after surgery. Thus numerous studies have investigated the efficacy of neoadjuvant therapies for high‐risk PC patients; however, no protocol has been established. This study aimed to assess the effect of androgen deprivation therapy combined with low‐dose estramustine phosphate (EMP) on BCR compared with androgen deprivation therapy (ADT) alone in high‐ and very high‐risk patients with PC.

Methods

This retrospective study targeted patients with PC meeting the National Comprehensive Cancer Network high‐risk criteria (cT1‐4N0M0), with 173 patients in the exposure group who received neoadjuvant chemohormonal therapy (gonadotropin‐releasing hormone [GnRH] antagonist combined with low‐dose EMP), and 490 patients in the control group treated with and neoadjuvant hormone therapy (NHT) (ADT ± first‐generation anti‐androgens). Data for each group were extracted from a database of patients who underwent robot‐assisted laparoscopic prostatectomy at 25 tertiary care centers across Japan between 2011 and 2023. The inverse probability of treatment weighting was used to adjust for baseline differences. The primary outcome was BCR‐free survival, with hazard ratios (HRs) calculated using a Cox proportional hazards model between the high‐risk and very high‐risk groups.

Results

After adjustment, the standardized mean difference was < 0.1. The exposure group had 3 and 5‐year BCR‐free survival rates of 82.1% and 74.6%, respectively, compared with 70.8% and 64.4% in the control group (HR: 0.55; 95% confidence interval [CI]: 0.35–0.88). For high‐risk patients, the rates were 87.1% and 84.2% at both 3 and 5 years in the intervention group and 83.5% and 75.0% in the control group (HR: 0.66; 95% CI: 0.30–1.47). For very high‐risk patients, the 3‐year and 5‐year rates were 75.3% and 65.7% in the intervention group and 57.3% and 53.6% in the control group (HR: 0.53; 95% CI: 0.30–0.92).

Conclusions

In patients with very high‐risk PC undergoing robot‐assisted laparoscopic prostatectomy, a GnRH antagonist and low‐dose EMP yielded better BCR‐free survival outcomes than NHT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsEstramustineProstatectomyGonadotropin-Releasing HormoneNeoadjuvant TherapyRobotic Surgical ProceduresHumansMaleRetrospective StudiesAgedMiddle AgedAntineoplastic Agents, HormonalAndrogen AntagonistsNeoplasm Recurrence, Local

Stichwörter der Autor:innen

estramustine phosphatehigh‐risk prostate cancerneoadjuvant chemohormonal therapy

Substanzen

EstramustineGonadotropin-Releasing HormoneAntineoplastic Agents, HormonalAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Urology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Department of Urology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Department of Urology, Akita University Graduate School of Medicine, Akita, Japan.
  • Department of Urology, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Urology, Hyogo Medical University, Hyogo, Japan.

ORCID-Profile: Takanari Kambe, Toshinari Yamasaki

Zitieren

APA

Kambe, T., Kubota, M., Yamasaki, T., Kawakita, M., Murata, S., Hattori, Y., Tohi, Y., Sekine, Y., Kurahashi, R., Shimatani, K., Sawada, A., Negoro, H., Saito, R., Goto, T., & Kobayashi, T. (2025). Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low‐Dose Estramustine in Very High‐Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy. The Prostate. https://doi.org/10.1002/pros.24875

Vancouver

Kambe T, Kubota M, Yamasaki T, Kawakita M, Murata S, Hattori Y, et al. Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low‐Dose Estramustine in Very High‐Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy. The Prostate. 2025. doi:10.1002/pros.24875

BibTeX
@article{Kambe2025,
  author = {Kambe, Takanari and Kubota, Masashi and Yamasaki, Toshinari and Kawakita, Mutsushi and Murata, Shiori and Hattori, Yuto and Tohi, Yoichiro and Sekine, Yuya and Kurahashi, Ryoma and Shimatani, Kimihiro and Sawada, Atsuro and Negoro, Hiromitsu and Saito, Ryoichi and Goto, Takayuki and Kobayashi, Takashi},
  title = {Impact of Neoadjuvant Chemohormonal Therapy With GnRH Antagonist and Low‐Dose Estramustine in Very High‐Risk Prostate Cancer Undergoing Robotic Radical Prostatectomy},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.24875}
}
Kostenlos starten →